Draft Guidance on Requesting ANDA Decision Reconsideration

January 2, 2018

[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]

CDER issued draft guidance on procedures to be followed by ANDA applicants requesting reconsideration at the division level of review decisions.

[/membership]

News Brief

Primary Sidebar

Footer

INTERNATIONAL PHARMACEUTICAL QUALITY

Home	SIGN UP: News Alerts	News In Depth	FDA Warning Letters	FAQs	About Us
ADMIN	Subscribe	Updates In Brief	EMA Non-Compliance Reports	Privacy Policy	Staff
	Advertise	Monthly Updates	FDA Drug Recalls	Help!

Copyright © 2021 International Pharmaceutical Quality (ISSN 1937-6901) All rights reserved.
IPQ Publications LLC, 3836 Fulton St. NW, Washington, DC 20007. Content cannot be transmitted except for internal use by companies/organizations that have licenses. For reprints and subscription information, contact Jonathan Trethowan.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.